LakePharma will operate as part of Curia’s R&D division, led by Christopher Conway, President, R&D
Curia, formerly AMRI, a global CDMO, has completed the transaction to acquire LakePharma, a privately held biologics drug discovery CDMO with operations in California, Massachusetts and Texas. With this acquisition, it says, Curia can offer expertise in large and small molecules from drug discovery through drug substance manufacturing, sterile injectable formulation and fill-finish production.
“The completion of LakePharma transforms our biologics offering, enabling us to provide end-to-end capabilities to customers, based on deep scientific expertise and an integrated technology platform,” said Curia Chairman and CEO John Ratliff.
“Together with Integrity Bio, now part of Curia, this transaction represents a major milestone in our growth journey and means we can deliver seamless solutions and expanded capacity for biologics customers. I’m delighted to welcome our new colleagues from LakePharma to the global Curia community and to work with them to advance our customers from curiosity to cure.”
LakePharma will operate as part of Curia’s R&D division, led by Christopher Conway, President, R&D. Hua Tu, LakePharma’s founder and CEO, will serve on Curia’s executive team as CTO. LakePharma and its ‘The Biologics Company’ brand will migrate to the Curia brand in the future. It will continue to use its name for an interim period, adding ‘Now part of Curia’ to its logo.